A Phase 1 interventional study of MK-8226 BID, 1 mg and MK-8266 BID, 1.8 mg in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-08-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Hypertension by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hypertension · Merck & Co., Inc.
Among the 33 studies in Hypertension by Merck & Co., Inc, this one is the 20th largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2010, is one of 17 in phase 1, and was the 18th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 33 studies in Hypertension by Merck & Co., Inc is open now. The open studies under Hypertension, anywhere →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 55 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 84 across the 32 interventional studies, 450 across the 1 observational. Of the 33 that completed or were terminated, 27 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Hypertension by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated adverse events (AEs), study discontinuation due to AEs, and pharmacodynamics of MK-8266 in male participants with mild to moderate hypertension.
This study evaluated AEs, discontinuation due to AEs, and effects on hemodynamic parameters, including systolic blood pressure (SBP) and aortic augmentation index (AIx), following multiple oral doses of MK-8266. Five serial panels, each consisting of eight participants (40 participants in Panels A, B, C, D, and E), were randomized to receive either MK-8266 or matching placebo twice daily (BID) or three times daily (TID) for 10 consecutive days. Although the original plan was to evaluate MK-8266 treatment in Panels D and E using both BID and TID regimens, the study actually evaluated identical TID regimens in these panels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MK-8266 1 mg (0.7 mg in the morning \[AM\] + 0.3 mg in the evening \[PM\]), or as matching placebo BID.
Drug: MK-8226 BID, 1 mg · Drug: Placebo BID (Panel A)
MK-8266 1.8 mg (1 mg in the AM + 0.8 mg in the PM), or as matching placebo BID.
Drug: MK-8266 BID, 1.8 mg · Drug: Placebo BID (Panel B)
MK-8266 TID, 1.8 mg (0.6 mg every 6 hours \[q6hr\]), or as matching placebo TID.
Drug: MK-8266 TID, 1.8 mg · Drug: Placebo TID (Panel C)
MK-8266 TID (Panel D), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel D was completed prior to initiation of Panel E.
Drug: MK-8266 TID, 2.4 mg · Drug: Placebo TID (Panel D)
MK-8266 TID (Panel E), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel E was initiated after completion of Panel D.
Drug: MK-8266 TID, 2.4 mg · Drug: Placebo TID (Panel E)
MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
Also known as: MK-8266
MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
Also known as: MK-8266
MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
Also known as: MK-8266
MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
Also known as: MK-8266
MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
Also known as: MK-8266
Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
Participants Receiving MK-8266 or Placebo Who Experienced At Least One Adverse Event (AE) During Treatment and Postdose Follow-up
Assessment of the number of participants with at least one clinical or laboratory AE in those receiving multiple oral doses of MK-8266. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product.
Time frame: Up to 24 days
Participants Receiving MK-8266 or Placebo Who Discontinued Treatment Due to an AE
Assessment of the number of participants receiving MK-8266 who discontinued therapy due to an AE over 10 days of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. The number of participants in any treatment group who discontinued therapy due to an AE was primarily assessed for Days 0-10.
Time frame: Up to 10 days
Change From Baseline in Systolic Blood Pressure (SBP) Following Multiple Oral Doses of MK-8266 or Placebo
Assessment of the change from baseline in SBP, obtained using a validated, semi-automated oscillometric device. Evaluated for MK-8266 relative to placebo in participants, as measured by the time weighted average change over 24 hours postdose (TWA\^0-24hrs) on dosing Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this analysis.
Time frame: Baseline and Day 10
Heart Rate (HR) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo
Assessment of HR (beats/min) on Day 10 (24-hours postdose) with MK-8266 relative to placebo in participants, as measured by the time weighted average change over 24 hours postdose (TWA\^0-24hrs). Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this analysis. Baseline HR values are shown in the Baseline Characteristics section for Panels A, B, C, D, E.
Time frame: Day 10 (24 hours postdose)
Aortic Augmentation Index (AIx) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo
Assessment of the central, ascending aortic blood pressure augmentation index (AIx), based on measurement of central pulse pressure at selected time points on Day 10, as measured by applanation tonometry of the radial artery. This outcome measure assessed the time weighted average change over 24 hours postdose (TWA\^0-24hrs) on dosing Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this assessment.
Time frame: Day 10
Change From Baseline in Cyclic Guanosine Monophosphate (cGMP) Following Multiple Oral Doses of MK-8266 or Placebo
Assessment of whole blood samples for cGMP analysis, based on samples obtained predose as well as 4 and 24 hours postdose on Day 1 and Day 10, and predose only on Day 4. The change from baseline in cGMP was assessed at 24 hours postdose on Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this assessment.
Time frame: Baseline and Day 10
Percent Inhibition of Platelet Aggregation Induced by Adenosine Diphosphate (ADP) Following Multiple Oral Doses of MK-8266 or Placebo
The percent inhibition of ADP-induced platelet aggregation from Baseline to 5 hours postdose on Day 10 was assessed and is summarized here. Platelet aggregation was initiated by addition of ADP (2.5 µM) to the participant's blood sample. Aggregation was followed for 5 minutes after addition of the agonist, and the maximum percent of light transmission (extent of aggregation) obtained during this period, as well as the instrument-calculated slope (rate of aggregation), were reported. Post treatment platelet aggregation is expressed as a percent of each participant's pretreatment level of aggregation. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this summary. The data are very limited. On Day 10 only 8 participants received MK-8266 0.8 mg TID and 3 participants received placebo.
Time frame: Baseline and Day 10 (5 hours postdose)
Percent Inhibition of Platelet Aggregation Induced by Collagen Following Multiple Oral Doses of MK-8266 or Placebo
The percent inhibition of collagen-induced platelet aggregation from Baseline to 5 hours postdose on Day 10 was assessed and is summarized here. Platelet aggregation was initiated by addition of collagen (2 µg/mL) to the participant's blood sample. Aggregation was followed for 5 minutes after addition of the agonist, and the maximum percent of light transmission (extent of aggregation) obtained during this period, as well as the instrument-calculated slope (rate of aggregation), were reported. Post treatment platelet aggregation is expressed as a percent of each participant's pretreatment level of aggregation. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this summary. The data are very limited. On Day 10, only 8 participants received MK-8266 0.8 mg TID and 3 participants received placebo.
Time frame: Baseline and Day 10 (5 hours postdose)
| Milestone | Panel A: MK-8266 BID (1 mg) | Panel A: Placebo BID | Panel B: MK-8266 BID (1.8 mg) | Panel B: Placebo BID | Panel C: MK-8266 TID (1.8 mg) | Panel C: Placebo TID | Panel D: MK-8266 TID (2.4 mg) | Panel D: Placebo TID | Panel E: MK-8266 TID (2.4 mg) | Panel E: Placebo TID |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 2 | 6 | 2 | 6 | 2 | 6 | 2 | 6 | 2 |
| Completed | 6 | 2 | 5 | 2 | 5 | 2 | 4 | 2 | 4 | 1 |
| Not completed | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Met stopping criteria per protocol | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 2 | 0 |
Assessment of the number of participants with at least one clinical or laboratory AE in those receiving multiple oral doses of MK-8266. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product.
| Count of Participants | Panel A: MK-8266 BID (1 mg) | Panel A: Placebo | Panel B: MK-8266 BID (1.8 mg) | Panel B: Placebo | Panel C: MK-8266 TID (1.8 mg) | Panel C: Placebo | Panel D: MK-8266 TID (2.4 mg) | Panel D: Placebo | Panel E: MK-8266 TID (2.4 mg) | Panel E: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Participants Receiving MK-8266 or Placebo Who Experienced At Least One Adverse Event (AE) During Treatment and Postdose Follow-up | 5 | 0 | 5 | 1 | 3 | 1 | 4 | 1 | 5 | 2 |
Assessment of the number of participants receiving MK-8266 who discontinued therapy due to an AE over 10 days of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. The number of participants in any treatment group who discontinued therapy due to an AE was primarily assessed for Days 0-10.
| Count of Participants | Panel A: MK-8266 BID (1 mg) | Panel A: Placebo | Panel B: MK-8266 BID (1.8 mg) | Panel B: Placebo | Panel C: MK-8266 TID, 1.8 mg | Panel C: Placebo | Panel D: MK-8266 TID (2.4 mg) | Panel D: Placebo | Panel E: MK-8266 2.4 mg TID | Panel E: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Participants Receiving MK-8266 or Placebo Who Discontinued Treatment Due to an AE | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Assessment of the change from baseline in SBP, obtained using a validated, semi-automated oscillometric device. Evaluated for MK-8266 relative to placebo in participants, as measured by the time weighted average change over 24 hours postdose (TWA\^0-24hrs) on dosing Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this analysis.
| Millimeters of mercury (mmHg) | Panel A: MK-8266 BID, 1 mg | Panel B: MK-8266 BID, 1.8 mg | Panel C: MK-8266 TID, 1.8 mg | Panels D & E Combined: MK-8266 TID, 2.4 mg | Pooled Placebo |
|---|---|---|---|---|---|
| Baseline value | 141.5 ± 8.96 | 132.6 ± 6.66 | 148.6 ± 23.77 | 134.5 ± 8.98 | 146.7 ± 12.07 |
| Change from Baseline at Day 10 | -5.09 ± 7.04 | -2.18 ± 6.80 | -4.78 ± 7.64 | 0.77 ± 6.62 | -3.18 ± 7.72 |
Assessment of HR (beats/min) on Day 10 (24-hours postdose) with MK-8266 relative to placebo in participants, as measured by the time weighted average change over 24 hours postdose (TWA\^0-24hrs). Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this analysis. Baseline HR values are shown in the Baseline Characteristics section for Panels A, B, C, D, E.
| Beats per minute | Panel A: MK-8266 BID (1 mg) | Panel B: MK-8266 BID (1.8 mg) | Panel C: MK-8266 TID (1.8 mg) | Panels D & E Combined: MK-8266 TID: MK-8266 TID (2.4 mg) | Pooled Placebo |
|---|---|---|---|---|---|
| Heart Rate (HR) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo | 65.89 ± 5.59 | 69.32 ± 7.87 | 62.30 ± 5.28 | 66.10 ± 5.38 | 62.04 ± 5.98 |
Assessment of the central, ascending aortic blood pressure augmentation index (AIx), based on measurement of central pulse pressure at selected time points on Day 10, as measured by applanation tonometry of the radial artery. This outcome measure assessed the time weighted average change over 24 hours postdose (TWA\^0-24hrs) on dosing Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this assessment.
| mmHg | Panel A: MK-8266 BID, 1 mg | Panel B: MK-8266 BID, 1.8 mg | Panel C: MK-8266 TID, 1.8 mg | Panels D & E Combined: MK-8266 TID, 2.4 mg | Pooled Placebo |
|---|---|---|---|---|---|
| Aortic Augmentation Index (AIx) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo | 8.81 ± 4.86 | 7.45 ± 2.59 | 13.50 ± 8.95 | 11.89 ± 7.00 | 18.68 ± 6.68 |
Assessment of whole blood samples for cGMP analysis, based on samples obtained predose as well as 4 and 24 hours postdose on Day 1 and Day 10, and predose only on Day 4. The change from baseline in cGMP was assessed at 24 hours postdose on Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this assessment.
| nanomoles (nM) | Panel A: MK-8266 BID, 1 mg | Panel B: MK-8266 BID, 1.8 mg | Panel C: MK-8266 TID, 1.8 mg | Panels D & E Combined: MK-8266 TID, 2.4 mg | Pooled Placebo |
|---|---|---|---|---|---|
| Baseline value | 1.61 ± 0.77 | 0.74 ± 0.50 | 1.69 ± 1.15 | 2.68 ± 1.29 | 0.54 ± 0.21 |
| Change from Baseline at Day 10 | 1.34 ± 2.74 | 1.74 ± 4.62 | 0.43 ± 0.66 | 0.81 ± 2.78 | 1.05 ± 1.16 |
The percent inhibition of ADP-induced platelet aggregation from Baseline to 5 hours postdose on Day 10 was assessed and is summarized here. Platelet aggregation was initiated by addition of ADP (2.5 µM) to the participant's blood sample. Aggregation was followed for 5 minutes after addition of the agonist, and the maximum percent of light transmission (extent of aggregation) obtained during this period, as well as the instrument-calculated slope (rate of aggregation), were reported. Post treatment platelet aggregation is expressed as a percent of each participant's pretreatment level of aggregation. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this summary. The data are very limited. On Day 10 only 8 participants received MK-8266 0.8 mg TID and 3 participants received placebo.
| Percent inhibition | Panels D & E Combined: MK-8266 TID (2.4 mg) | Placebo |
|---|---|---|
| Percent Inhibition of Platelet Aggregation Induced by Adenosine Diphosphate (ADP) Following Multiple Oral Doses of MK-8266 or Placebo | -12.3 ± 29.81 | -12.4 ± 18.89 |
The percent inhibition of collagen-induced platelet aggregation from Baseline to 5 hours postdose on Day 10 was assessed and is summarized here. Platelet aggregation was initiated by addition of collagen (2 µg/mL) to the participant's blood sample. Aggregation was followed for 5 minutes after addition of the agonist, and the maximum percent of light transmission (extent of aggregation) obtained during this period, as well as the instrument-calculated slope (rate of aggregation), were reported. Post treatment platelet aggregation is expressed as a percent of each participant's pretreatment level of aggregation. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this summary. The data are very limited. On Day 10, only 8 participants received MK-8266 0.8 mg TID and 3 participants received placebo.
| Percent inhibition | Panels D & E Combined: MK-8266 TID (2.4 mg) | Placebo |
|---|---|---|
| Percent Inhibition of Platelet Aggregation Induced by Collagen Following Multiple Oral Doses of MK-8266 or Placebo | -17.7 ± 26.30 | -8.87 ± 33.76 |
Collected over 11 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panel A: MK-8266 BID, 1 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Panel A: Placebo BID | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Panel B: MK-8266 BID, 1.8 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Panel B: Placebo BID | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Panel C: MK-8266 TID, 1.8 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Panel C: Placebo TID | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Panel D: MK-8266 TID, 2.4 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Panel D: Placebo TID | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Panel E: MK-8266 TID, 2.4 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Panel E: Placebo TID | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Panel A: MK-8266 BID, 1 mg | Panel A: Placebo BID | Panel B: MK-8266 BID, 1.8 mg | Panel B: Placebo BID | Panel C: MK-8266 TID, 1.8 mg | Panel C: Placebo TID | Panel D: MK-8266 TID, 2.4 mg | Panel D: Placebo TID | Panel E: MK-8266 TID, 2.4 mg | Panel E: Placebo TID |
|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/6 | 0/2 | 4/6 | 1/2 | 3/6 | 1/2 | 2/6 | 1/2 | 4/6 | 1/2 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 1/2 | 0/6 | 0/2 | 0/6 | 0/2 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 1/2 | 0/6 | 0/2 | 0/6 | 0/2 |
| NauseaGastrointestinal disorders | 0/6 | 0/2 | 1/6 | 1/2 | 0/6 | 0/2 | 0/6 | 1/2 | 1/6 | 0/2 |
| PruritusSkin and subcutaneous tissue disorders | 1/6 | 0/2 | 1/6 | 0/2 | 0/6 | 1/2 | 0/6 | 0/2 | 0/6 | 0/2 |
| HypertensionVascular disorders | 0/6 | 0/2 | 1/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 1/2 |
| Abnormal sensation in eyeEye disorders | 0/6 | 0/2 | 2/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 |
| Supraventricular tachycardiaCardiac disorders | 1/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 |
| Ventricular tachycardiaCardiac disorders | 1/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 |
| Ear painEar and labyrinth disorders | 1/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 |
| Age, Continuous(years) | Panel A: MK-8266 BID, 1 mg | Panel A: Placebo BID | Panel B: MK-8266 BID, 1.8 mg | Panel B: Placebo BID | Panel C: MK-8266 TID, 1.8 mg | Panel C: Placebo TID | Panel D: MK-8266 TID, 2.4 mg | Panel D: Placebo TID | Panel E: MK-8266 TID, 2.4 mg | Panel E: Placebo TID | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 49.2 ± 1.5 | 47.5 ± 4.9 | 45.5 ± 7.8 | 52.0 ± 1.4 | 46.5 ± 3.4 | 54.0 ± 1.4 | 46.2 ± 5.5 | 46.5 ± 7.8 | 47.2 ± 5.2 | 48.5 ± 0.7 | 47.6 ± 4.9 |
| Sex: Female, Male(Participants) | Panel A: MK-8266 BID, 1 mg | Panel A: Placebo BID | Panel B: MK-8266 BID, 1.8 mg | Panel B: Placebo BID | Panel C: MK-8266 TID, 1.8 mg | Panel C: Placebo TID | Panel D: MK-8266 TID, 2.4 mg | Panel D: Placebo TID | Panel E: MK-8266 TID, 2.4 mg | Panel E: Placebo TID | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 2 | 6 | 2 | 6 | 2 | 6 | 2 | 6 | 2 | 40 |
| Baseline HR(Beats per minute) | Panel A: MK-8266 BID, 1 mg | Panel A: Placebo BID | Panel B: MK-8266 BID, 1.8 mg | Panel B: Placebo BID | Panel C: MK-8266 TID, 1.8 mg | Panel C: Placebo TID | Panel D: MK-8266 TID, 2.4 mg | Panel D: Placebo TID | Panel E: MK-8266 TID, 2.4 mg | Panel E: Placebo TID | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 70 (53 to 91) | 90 (71 to 108) | 79 (71 to 92) | 89 (79 to 99) | 74 (43 to 85) | 69 (65 to 72) | 72 (59 to 84) | 88 (79 to 96) | 74 (60 to 127) | 81 (67 to 94) | 73 (43 to 127) |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from Mar 2010 to primary completion in Nov 2010, 8 months.
Results were first posted in Aug 2019, 8 years 9 months after primary completion.
Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 8 months is above that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Solrikitug · MK-8266